Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13045-015-0161-1 http://scihub22266oqcxt.onion/10.1186/s13045-015-0161-1 C4460883!4460883!26048374     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Hematol+Oncol 2015 ; 8 (ä): ä Nephropedia Template TP {{tp|p=26048374|t=2015. Targeting Wnt pathway in mantle cell lymphoma-initiating cells |pdf=|usr=}}{{26048374}} gab.com Text Targeting Wnt pathway in mantle cell lymphoma-initiating cells JO: J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26048374 #FOAvip Background: Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-Hodgkin?s lymphoma. Despite initial intense chemotherapy, up to 50 % of cases of MCL relapse often in a chemoresistant form. We hypothesized that the recently identified MCL-initiating cells (MCL-ICs) are the main reason for relapse and chemoresistance of MCL. Cancer stem cell-related pathways such as Wnt could be responsible for their maintenance and survival. Methods: We isolated MCL-ICs from primary MCL cells on the basis of a defined marker expression pattern (CD34-CD3-CD45+CD19-) and investigated Wnt pathway expression. We also tested the potential of Wnt pathway inhibitors in elimination of MCL-ICs. Results: We showed that MCL-ICs are resistant to genotoxic agents vincristine, doxorubicin, and the newly approved Burton tyrosine kinase (BTK) inhibitor ibrutinib. We confirmed the differential up-regulation of Wnt pathway in MCL-ICs. Indeed, MCL-ICs were particularly sensitive to Wnt pathway inhibitors. Targeting ?-catenin-TCF4 interaction with CCT036477, iCRT14, or PKF118-310 preferentially eliminated the MCL-ICs. Conclusions: Our results suggest that Wnt signaling is critical for the maintenance and survival of MCL-ICs, and effective MCL therapy should aim to eliminate MCL-ICs through Wnt signaling inhibitors. Electronic supplementary material: The online version of this article (doi:10.1186/s13045-015-0161-1) contains supplementary material, which is available to authorized users. Twit Text FOAVip Targeting Wnt pathway in mantle cell lymphoma-initiating cells ????J Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26048374 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26048374 #FOAvip English Wikipedia <ref>{{Cite pmid|26048374}}</ref> Targeting Wnt pathway in mantle cell lymphoma-initiating cells #MMPMID26048374 Mathur R; Sehgal L; Braun FK; Berkova Z; Romaguerra J; Wang M; Rodriguez MA; Fayad L; Neelapu SS; Samaniego F J Hematol Oncol 2015[]; 8 (ä): ä PMID26048374show ga Background: Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-Hodgkin?s lymphoma. Despite initial intense chemotherapy, up to 50 % of cases of MCL relapse often in a chemoresistant form. We hypothesized that the recently identified MCL-initiating cells (MCL-ICs) are the main reason for relapse and chemoresistance of MCL. Cancer stem cell-related pathways such as Wnt could be responsible for their maintenance and survival. Methods: We isolated MCL-ICs from primary MCL cells on the basis of a defined marker expression pattern (CD34-CD3-CD45+CD19-) and investigated Wnt pathway expression. We also tested the potential of Wnt pathway inhibitors in elimination of MCL-ICs. Results: We showed that MCL-ICs are resistant to genotoxic agents vincristine, doxorubicin, and the newly approved Burton tyrosine kinase (BTK) inhibitor ibrutinib. We confirmed the differential up-regulation of Wnt pathway in MCL-ICs. Indeed, MCL-ICs were particularly sensitive to Wnt pathway inhibitors. Targeting ?-catenin-TCF4 interaction with CCT036477, iCRT14, or PKF118-310 preferentially eliminated the MCL-ICs. Conclusions: Our results suggest that Wnt signaling is critical for the maintenance and survival of MCL-ICs, and effective MCL therapy should aim to eliminate MCL-ICs through Wnt signaling inhibitors. Electronic supplementary material: The online version of this article (doi:10.1186/s13045-015-0161-1) contains supplementary material, which is available to authorized users. äTargeting Wnt pathway in mantle cell lymphoma-initiating cells (epmc).pdf DeepDyve Pubget Overpricing